SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001213900-20-010929
Filing Date
2020-05-04
Accepted
2020-05-04 17:22:32
Documents
1
Group Members
ENRICO CAVAZZAFRANCESCA CAVAZZAMARTINA CAVAZZA PRETAPAOLO CAVAZZASILVIA CAVAZZA

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 TO SCHEDULE 13D ea121349-13da1essetifin_fenn.htm SC 13D/A 143860
  Complete submission text file 0001213900-20-010929.txt   145756
Mailing Address VIA SUDAFRICA 20 ROME L6 00144
Business Address
Essetifin SPA (Filed by) CIK: 0001092601 (see all company filings)

Fiscal Year End: 1231
Type: SC 13D/A

Mailing Address PO BOX 13628 68 TW ALEXANDER DRIVE RESEARCH TRIANGLE PARK NC 27709
Business Address PO BOX 13628 68 TW ALEXANDER DRIVE RESEARCH TRIANGLE PARK NC 27709 (919) 636-4530
FENNEC PHARMACEUTICALS INC. (Subject) CIK: 0001211583 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-80470 | Film No.: 20845932
SIC: 2836 Biological Products, (No Diagnostic Substances)